当前位置:首页 - 行情中心 - 威尔药业(603351) - 财务分析 - 利润表

威尔药业

(603351)

  

流通市值:36.79亿  总市值:36.79亿
流通股本:1.35亿   总股本:1.35亿

利润表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、营业总收入1,018,241,707.95673,722,955.67349,725,188.551,296,753,389.06
  营业收入1,018,241,707.95673,722,955.67349,725,188.551,296,753,389.06
二、营业总成本892,228,158.27588,979,381.47307,861,914.391,137,417,233.03
  营业成本728,251,744.26484,557,044.44258,644,574.16929,479,269.55
  税金及附加6,602,047.194,373,876.452,194,359.968,701,785.7
  销售费用13,273,755.937,317,179.473,064,721.6914,471,230.01
  管理费用75,185,518.3148,425,467.7522,880,583.92101,371,471.57
  研发费用60,977,699.6838,837,337.1118,198,856.6171,561,298.63
  财务费用7,937,392.95,468,476.252,878,818.0511,832,177.57
  其中:利息费用8,022,178.255,955,785.212,921,468.8413,837,458.66
  其中:利息收入428,666.71176,372.05144,450.19925,452.55
三、其他经营收益
  加:公允价值变动收益4,240,786.221,736.22-12,072,961.13
  加:投资收益15,363.51---68,939.98
  资产处置收益16,250.036,484.576,484.57-
  资产减值损失(新)-2,467,637.19-2,467,637.19--9,014,547.81
  信用减值损失(新)-264,721.58-449,956.84-219,574.21-357,076.34
  其他收益6,368,256.794,116,917.551,369,147.8410,381,884.36
四、营业利润133,921,847.4685,951,118.5143,019,332.36172,350,437.39
  减:营业外支出342,331.8994,473.0269,616.87219,173.52
五、利润总额133,579,515.5785,856,645.4942,949,715.49172,131,263.87
  减:所得税费用21,840,816.0814,554,015.037,183,536.9526,925,425.17
六、净利润111,738,699.4971,302,630.4635,766,178.54145,205,838.7
(一)按经营持续性分类
  持续经营净利润111,738,699.4971,302,630.4635,766,178.54145,205,838.7
(二)按所有权归属分类
  归属于母公司股东的净利润114,065,424.6972,766,854.5236,587,563.15146,421,823.99
  少数股东损益-2,326,725.2-1,464,224.06-821,384.61-1,215,985.29
  扣除非经常损益后的净利润110,469,598.9572,248,911.4936,375,002.98135,856,039.41
七、每股收益
  (一)基本每股收益0.840.540.271.08
  (二)稀释每股收益0.840.540.271.08
九、综合收益总额111,738,699.4971,302,630.4635,766,178.54145,205,838.7
  归属于母公司股东的综合收益总额114,065,424.6972,766,854.5236,587,563.15146,421,823.99
  归属于少数股东的综合收益总额-2,326,725.2-1,464,224.06-821,384.61-1,215,985.29
公告日期2025-10-302025-08-202025-04-222025-04-22
审计意见(境内)标准无保留意见
TOP↑